Results 81 to 90 of about 3,475,545 (379)

Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease

Annals of Clinical and Translational Neurology, 2022
AbstractBlood‐based phosphorylated tau (Ptau) 181 and 217 biomarkers are sensitive and specific for Alzheimer's disease. In this racial/ethnically diverse cohort study, participants were classified as biomarker positive (Ptau+) or negative (Ptau‐) based on Ptau 181 and 217 concentrations and as cognitively impaired (Sym) or unimpaired (Asym).
Adam M. Brickman, Jennifer J. Manly, Lawrence S. Honig, Danurys Sanchez, Dolly Reyes‐Dumeyer, Rafael A. Lantigua, Jean Paul Vonsattel, Andrew F. Teich, Min Suk Kang, Jeffrey L. Dage, Richard Mayeux   +10 more
openaire   +3 more sources

Levels of bioactive endogenous lipids and health-related quality of life in Chronic Idiopathic Axonal Polyneuropathy

Upsala Journal of Medical Sciences, 2022
Background: Although neuropathic pain is a significant problem in polyneuropathy, the underlying molecular mechanisms are poorly understood. The endogenous bioactive lipids 2-arachidonoyl-glycerol (2-AG), oleoylethanolamide (OEA), palmitoylethanolamide ...
Jonas Lind, Niclas Stensson, Björn Gerdle, Nazdar Ghafouri   +3 more
doaj   +1 more source

Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies

Alzheimer's & Dementia
Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET ...
P. Diaz-Galvan, S. Przybelski, A. Algeciras-Schimnich, D. Figdore, T. Lesnick, C. Schwarz, M. Senjem, J. Gunter, C. R. Jack, Paul H. Min, Manoj K. Jain, T. Miyagawa, L. Forsberg, J. Fields, R. Savica, J. Graff‐Radford, V. Ramanan, David T Jones, H. Botha, E. S. St. Louis, D. Knopman, N. Graff-Radford, T. Ferman, R. C. Petersen, V. Lowe, B. Boeve, K. Kantarci   +26 more
semanticscholar   +1 more source

Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology

Alzheimer's & Dementia, 2022
The impact of hepatorenal function on plasma biomarkers of neuropathology is unknown. Herein, we measured several plasma biomarkers in patients with cirrhosis.
Kacey Berry, B. Asken, Joshua Grab, Brandon Chan, Argentina Lario Lago, Randi J. Wong, Srilakshmi Seetharaman, Sara C. LaHue, K. Possin, J. Rojas, J. Kramer, A. Boxer, J. Lai, L. Vandevrede   +13 more
semanticscholar   +1 more source

The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension [PDF]

, 2015
We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive
Agata Bielecka-Dabrowa, Anna Gluba-Brzózka, Campeau, Jacek Rysz, Li, Maciej Banach, Marta Michalska-Kasiczak, Małgorzata Misztal, McCullough, Ravassa, Wei   +10 more
core   +2 more sources

265 PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION: [PDF]

Heart, 2013
Introduction MicroRNAs (miRNAs) are small non-coding RNAs that are also detectable in the blood. Circulating levels of miRNAs have been measured in various epidemiological studies, but the effects of medication are unclear. To address these uncertainties, we aimed to (1) compare the levels of miRNAs in different sample types, (2) assess how miRNAs
Willeit, P, Zampetaki, A, Kaudewitz, D, Lee, R, Dudek, K, King, A, Kirkby, N, Markus, H, Warner, T, Kiechl, S, Morton, A, Channon, K, Storey, R, Mayr, M   +13 more
openaire   +2 more sources

Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy Controls

Neurotrauma Reports
The objective of this study was to compare participants at-risk for trauma-related neurodegeneration to a healthy control group on outcomes associated with Alzheimer’s disease (AD), such as subjective symptoms, neurocognitive performance, plasma ...
Shawn R. Eagle, Ava Puccio, Sarah Svirsky, James Mountz, Charles Laymon, Allison Borasso, Luke Henry, David O. Okonkwo   +7 more
doaj   +1 more source

Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau)181+231.
Madeline Ally, Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari, Hugo J. Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin, Lindsay A. Farrer, Gyungah R. Jun, Katherine W. Turk, Andrew E. Budson, Maureen K. O'Connor, Rhoda Au, Lee E. Goldstein, Neil W. Kowall, Ronald Killiany, Robert A. Stern, Thor D. Stein, Ann C. McKee, Wei Qiao Qiu, Jesse Mez, Michael L. Alosco   +27 more
doaj   +1 more source

Semantic intrusion errors are associated with plasma Ptau-181 among persons with amnestic mild cognitive impairment who are amyloid positive

Frontiers in Neurology, 2023
IntroductionSemantic intrusion errors (SI) have distinguished between those with amnestic Mild Cognitive Impairment (aMCI) who are amyloid positive (A+) versus negative (A−) on positron emission tomography (PET).MethodThis study examines the association ...
Rosie E. Curiel Cid, Alexandra Ortega, Elizabeth A. Crocco, Diana Hincapie, Karen N. McFarland, Ranjan Duara, David Vaillancourt, Steven T. DeKosky, Glenn Smith, Efrosyni Sfakianaki, Monica Rosselli, Warren W. Barker, Malek Adjouadi, Yarlenis Barreto, Yuleidys Feito, David A. Loewenstein   +15 more
doaj   +1 more source

Characterizing Plasma Biomarkers of Alzheimer's in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort

Frontiers in Neurology, 2022
Background Due to their low cost, less invasive nature, and ready availability, plasma biomarkers of Alzheimer's disease have been proposed as one-time screening tools for clinical trials and research.
J. Hall, Melissa E. Petersen, L. Johnson, S. O'Bryant   +3 more
semanticscholar   +1 more source